Custodiol versus blood cardioplegia in pediatric cardiac surgery: a randomized controlled trial

• Published in: European journal of medical research 2023-10, Vol.28 (1), p.1-404, Article 404
• Main Authors: Elmahrouk, Ahmed F, Shihata, Mohammad S, AL-Radi, Osman O, Arafat, Amr A, Altowaity, Musleh, Alshaikh, Bayan A, Galal, Mohamed N, Bogis, Abdulbadee A, Al Omar, Haneen Y, Assiri, Wesal J, Jamjoom, Ahmed A
• Format: Article
• Language: English
• Subjects: Arrhythmia; Blood cardioplegia; Cardiac arrhythmia; Cardiac patients; Cardioplegia; Cardiovascular disease; Children; Clinical trials; Consent; Coronary artery bypass; Custadiol; Health aspects; Heart surgery; Histidine; Histidine-tryptophan-ketoglutarate; Hospitals; Intervention; Length of stay; Medical care; Mortality; Patients; Pediatric cardiology; Pediatrics; Quality management; Rankings; Surgeons; Surgery; Tryptophan
• ISSN: 2047-783X; 0949-2321; 2047-783X
• DOI: 10.1186/s40001-023-01372-4

Background Blood-based cardioplegia is the standard myocardial protection strategy in pediatric cardiac surgery. Custadiol (histidine-tryptophan-ketoglutarate), an alternative, may have some advantages but is potentially less effective at myocardial protection. This study aimed to test whether custadiol is not inferior to blood-based cardioplegia in pediatric cardiac surgery. Methods The study was designed as a randomized controlled trial with a blinded outcome assessment. All pediatric patients undergoing cardiac surgery with cardiopulmonary bypass and cardioplegia, including neonates, were eligible. Emergency surgery was excluded. The primary outcome was a composite of death within 30 days, an ICU stay longer than 5 days, or arrhythmia requiring intervention. Secondary endpoints included total hospital stay, inotropic score, cardiac troponin levels, ventricular function, and extended survival postdischarge. The sample size was determined a priori for a noninferiority design with an expected primary outcome of 40% and a clinical significance difference of 20%. Results Between January 2018 and January 2021, 226 patients, divided into the Custodiol cardioplegia (CC) group (n = 107) and the blood cardioplegia (BC) group (n = 119), completed the study protocol. There was no difference in the composite endpoint between the CC and BC groups, 65 (60.75%) vs. 71 (59.66%), respectively (P = 0.87). The total length of stay in the hospital was 14 (Q2-Q3: 10-19) days in the CC group vs. 13 (10-21) days in the BC group (P = 0.85). The inotropic score was not significantly different between the CC and BC groups, 5 (2.6-7.45) vs. 5 (2.6-7.5), respectively (P = 0.82). The cardiac troponin level and ventricular function did not differ significantly between the two groups (P = 0.34 and P = 0.85, respectively). The median duration of follow-up was 32.75 (Q2-Q3: 18.73-41.53) months, and there was no difference in survival between the two groups (log-rank P = 0.55). Conclusions Custodial cardioplegia is not inferior to blood cardioplegia for myocardial protection in pediatric patients. Trial registration The trial was registered in Clinicaltrials.gov, and the ClinicalTrials.gov Identifier number is NCT03082716 Date: 17/03/2017 Keywords: Cardioplegia, Custadiol, Blood cardioplegia, Histidine-tryptophan-ketoglutarate